Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and ...

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months)OS of 17.3 months in HR+ metastatic breast cancer ...

BriaCell Therapeutics Corporation announces updated phase 2 data of Bria-IMT, shows survival advantage over Trodelvy in metastatic breast cancer: Philadelphia & Vancouver, British ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best biotech stocks to buy according to billionaire Steve Cohen.

Innovative research explores targeted therapies for early triple-negative breast cancer, aiming to reduce toxicity while ...

Prospects for Gilead Sciences' Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still ...

Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy.

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...